A powerful Senate panel is urging federal agencies to make a number of surprising marijuana moves, including launching an effort to test products sold at dispensaries in states where marijuana has been legalized.
Concerned about a lack of data on the potency and purity of cannabis available to consumers, the U.S. Senate Appropriations Committee is directing federal agencies to formulate a "National Testing Program for Schedule I Marijuana-Derived Products."
The senators, in a report issued on Thursday, are instructing scientists at the National Institute on Drug Abuse (NIDA) to work with the Drug Enforcement Administration (DEA) to study marijuana samples in an effort to "provide robust reliable data that can inform policy."
Until 2014, NIDA funded a program for testing samples of illicit marijuana seized by law enforcement, but has never before officially analyzed cannabis products that are legally available to consumers under a growing number of state laws.
"The Committee believes that such research [on law-enforcement-seized cannabis], along with analysis of marijuana and marijuana-derived products sold commercially in dispensaries or online, is essential for informing substance abuse prevention efforts, public health policy, and law enforcement tactics across the Federal Government."
It is unknown how such a program would be carried out, for example whether it would involve sending teams of NIDA researchers to dispensaries to purchase marijuana for research, or if it would instead or in addition rely on DEA enforcement actions against the facilities and subsequent testing of seized products.
Separately in the report attached to legislation funding federal health programs, the Appropriations Committee also expressed alarm about "barriers to research" that are created by cannabis's current status under federal law, and is directing NIDA to compile a report about the matter.
Read the full article at Forbes.com.